Factors associated with vertebral fractures in men treated with androgen deprivation therapy for prostate cancer

Journal of Urology

Volumn 186, Issue 2, 2011, Pages 482-486

  Saylor, Philip J ^a,b   Morton, Ronald A ^a   Hancock, Michael L ^a   Barnette, K Gary ^a   Steiner, Mitchell S ^a   Smith, Matthew R ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^b GTx Inc   (United States)

Author keywords

androgens; bone; fractures; osteoporosis; prostatic neoplasms

Indexed keywords

GONADORELIN AGONIST; TOREMIFENE;

AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BONE DENSITY; CANCER HORMONE THERAPY; CAUCASIAN; CONTROLLED STUDY; DISEASE ASSOCIATION; HIP DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; ORCHIECTOMY; OSTEOPOROSIS; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SPINE DISEASE; TREATMENT DURATION; VERTEBRA FRACTURE;

AGED; ANDROGEN ANTAGONISTS; BONE DENSITY CONSERVATION AGENTS; DOUBLE-BLIND METHOD; HUMANS; MALE; PROSTATIC NEOPLASMS; RISK FACTORS; SPINAL FRACTURES; TOREMIFENE;

EID: 79960178576     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2011.03.111     Document Type: Article

References (29)

1. Bone Health and Osteoporosis: A Report of the Surgeon General 2004 U.S. Department of Health and Human Services, Office of the Surgeon General Rockville, Maryland
2. H.X. Jiang, S.R. Majumdar, and D.A. Dick Development and initial validation of a risk score for predicting in-hospital and 1-year mortality in patients with hip fractures J Bone Miner Res 20 2005 494
3. J.P. Bilezikian Osteoporosis in men J Clin Endocrinol Metab 84 1999 3431
4. A. Berruti, L. Dogliotti, and C. Terrone Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy J Urol 167 2002 2361
5. H.W. Daniell, S.R. Dunn, and D.W. Ferguson Progressive osteoporosis during androgen deprivation therapy for prostate cancer J Urol 163 2000 181
6. J.F. Maillefert, J. Sibilia, and F. Michel Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma J Urol 161 1999 1219
7. M.R. Smith, J. Eastham, and D.M. Gleason Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer J Urol 169 2003 2008
8. M.R. Smith, F.J. McGovern, and A.L. Zietman Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer N Engl J Med 345 2001 948
9. V.B. Shahinian, Y.F. Kuo, and J.L. Freeman Risk of fracture after androgen deprivation for prostate cancer N Engl J Med 352 2005 154
10. M.R. Smith, S.P. Boyce, and E. Moyneur Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer J Urol 175 2006 136
11. M.R. Smith, W.C. Lee, and J. Brandman Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer J Clin Oncol 23 2005 7897
12. B. Abrahamsen, M.F. Nielsen, and P. Eskildsen Fracture risk in Danish men with prostate cancer: a nationwide register study BJU Int 100 2007 749
13. J.A. Kanis, F. Borgstrom, and C. De Laet Assessment of fracture risk Osteoporos Int 16 2005 581
14. NCCN National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Prostate Cancer 2010 V. 3.2010
15. P.J. Saylor, D.S. Kaufman, and M.D. Michaelson Application of a fracture risk algorithm to men treated with androgen deprivation therapy for prostate cancer J Urol 183 2010 2200
16. R.A. Adler, F.W. Hastings, and V.I. Petkov Treatment thresholds for osteoporosis in men on androgen deprivation therapy: T-score versus FRAX Osteoporos Int 21 2010 647
17. M. Van der Klift, C.E. De Laet, and E.V. McCloskey The incidence of vertebral fractures in men and women: the Rotterdam Study J Bone Miner Res 17 2002 1051
18. E. Seeman, G. Bianchi, and S. Khosla Bone fragility in menwhere are we? Osteoporos Int 17 2006 1577
19. K.L. Stone, D.G. Seeley, and L.Y. Lui BMD at multiple sites and risk of fracture of multiple types: long-term results from the Study of Osteoporotic Fractures J Bone Miner Res 18 2003 1947
20. W.D. Leslie, J.F. Tsang, and P.A. Caetano Effectiveness of bone density measurement for predicting osteoporotic fractures in clinical practice J Clin Endocrinol Metab 92 2007 77
21. J.F. Tsang, and W.D. Leslie Exclusion of focal vertebral artifacts from spine bone densitometry and fracture prediction: a comparison of expert physicians, three computer algorithms, and the minimum vertebra J Bone Miner Res 22 2007 789
22. S.L. Greenspan, P. Coates, and S.M. Sereika Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer J Clin Endocrinol Metab 90 2005 6410
23. G.A. Greendale, S. Edelstein, and E. Barrett-Connor Endogenous sex steroids and bone mineral density in older women and men: the Rancho Bernardo Study J Bone Miner Res 12 1997 1833
24. S. Khosla, L.J. Melton 3rd, and E.J. Atkinson Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men J Clin Endocrinol Metab 86 2001 3555
25. C.W. Slemenda, C. Longcope, and L. Zhou Sex steroids and bone mass in older men Positive associations with serum estrogens and negative associations with androgens J Clin Invest 100 1997 1755
26. E.S. LeBlanc, C.M. Nielson, and L.M. Marshall The effects of serum testosterone, estradiol, and sex hormone binding globulin levels on fracture risk in older men J Clin Endocrinol Metab 94 2009 3337
27. D. Mellström, O. Johnell, and O. Ljunggren Free testosterone is an independent predictor of BMD and prevalent fractures in elderly men: MrOS Sweden J Bone Miner Res 21 2006 529
28. E. Barrett-Connor, J.E. Mueller, and D.G. von Mhlen Low levels of estradiol are associated with vertebral fractures in older men, but not women: the Rancho Bernardo Study J Clin Endocrinol Metab 85 2000 219
29. D. Mellström, L. Vandenput, and H. Mallmin Older men with low serum estradiol and high serum SHBG have an increased risk of fractures J Bone Miner Res 23 2008 1552